Your browser doesn't support javascript.
loading
Structure-Property Optimization of a Series of Imidazopyridines for Visceral Leishmaniasis.
Dichiara, Maria; Simpson, Quillon J; Quotadamo, Antonio; Jalani, Hitesh B; Huang, Anson X; Millard, Caroline C; Klug, Dana M; Tse, Edwin G; Todd, Matthew H; Silva, Daniel Gedder; da Silva Emery, Flavio; Carlson, J Eric; Zheng, Shao-Liang; Vleminckx, Margot; Matheeussen, An; Caljon, Guy; Pollastri, Michael P; Sjö, Peter; Perry, Benjamin; Ferrins, Lori.
Afiliação
  • Dichiara M; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Simpson QJ; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Quotadamo A; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Jalani HB; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Huang AX; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Millard CC; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Klug DM; School of Pharmacy, University College London, London WC1N 1AX, U.K.
  • Tse EG; School of Pharmacy, University College London, London WC1N 1AX, U.K.
  • Todd MH; School of Pharmacy, University College London, London WC1N 1AX, U.K.
  • Silva DG; School of Pharmacy, University College London, London WC1N 1AX, U.K.
  • da Silva Emery F; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903, Brazil.
  • Carlson JE; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903, Brazil.
  • Zheng SL; Rilas Technologies, Inc, 150-W New Boston Street, Woburn, Massachusetts 01801, United States.
  • Vleminckx M; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.
  • Matheeussen A; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Belgium.
  • Caljon G; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Belgium.
  • Pollastri MP; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Wilrijk, Belgium.
  • Sjö P; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
  • Perry B; Drugs for Neglected Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland.
  • Ferrins L; Drugs for Neglected Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland.
ACS Infect Dis ; 9(8): 1470-1487, 2023 08 11.
Article em En | MEDLINE | ID: mdl-37417544
ABSTRACT
Leishmaniasis is a collection of diseases caused by more than 20 Leishmania parasite species that manifest as either visceral, cutaneous, or mucocutaneous leishmaniasis. Despite the significant mortality and morbidity associated with leishmaniasis, it remains a neglected tropical disease. Existing treatments have variable efficacy, significant toxicity, rising resistance, and limited oral bioavailability, which necessitates the development of novel and affordable therapeutics. Here, we report on the continued optimization of a series of imidazopyridines for visceral leishmaniasis and a scaffold hop to a series of substituted 2-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles with improved absorption, distribution, metabolism, and elimination properties.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leishmaniose / Leishmania / Leishmaniose Visceral Limite: Humans Idioma: En Revista: ACS Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leishmaniose / Leishmania / Leishmaniose Visceral Limite: Humans Idioma: En Revista: ACS Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos